Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 20/20 | 0.41 |
| ▸ | SLC5A1 | P13866 | 12/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | SLC5A11 | Q8WWX8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2865858 | 0.89 | SLC5A2 (0.43) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL2869299 | 0.89 | SLC5A2 (0.45) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL2860892 | 0.88 | SLC5A2 (0.44) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL2864069 | 0.87 | SLC5A2 (0.44) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL2865646 | 0.85 | SLC5A2 (0.48) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL2864889 | 0.83 | SLC5A2 (0.46) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL2872902 | 0.83 | SLC5A2 (0.42) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL2867044 | 0.82 | SLC5A2 (0.45) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL3187076 | 0.82 | SLC5A2 (0.42) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL2863070 | 0.81 | SLC5A2 (0.43) | SLC5A2SLC5A1ADRA2ASLC5A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7847074-B2 | Processes for preparing of glucopyranosyl-substituted (ethynyl-benzyl)-benzene derivatives and intermediates thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-07 | — | — | US | disclosed |
| US-7772378-B2 | Glucopyranosyl-substituted ((hetero)arylethynyl-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-10 | — | — | US | disclosed |
| EP-1928852-A2 | PROCESSES FOR PREPARING OF GLUCOPYRANOSYL-SUBSTITUTED (ETHYNYL-BENZYL)-BENZENE DERIVATIVES AND INTERMEDIATES THEREOF | Boehringer Ingelheim International GmbH (DE) | 2008-06-11 | — | — | EP | disclosed |
| EP-1856082-A1 | GLUCOPYRANOSYL-SUBSTITUTED ((HETERO)ARYLETHYNYL-BENZYL)-BENZENE DERIVATIVES AND USE THEREOF AS SODIUM-DEPENDENT GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2007-11-21 | — | — | EP | disclosed |
| US-20070073046-A1 | Processes for preparing of glucopyranosyl-substituted (ethynyl-benzyl)-benzene derivatives and intermediates thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-03-29 | — | — | US | disclosed |
| WO-2007031548-A2 | PROCESSES FOR PREPARING OF GLUCOPYRANOSYL-SUBSTITUTED (ETHYNYL-BENZYL)-BENZENE DERIVATIVES AND INTERMEDIATES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-03-22 | — | — | WO | disclosed |
| WO-2006089872-A1 | GLUCOPYRANOSYL-SUBSTITUTED ( (HETERO)ARYLETHYNYL-BENZYD-BENZENE DERIVATIVES AND USE THEREOF AS SODIUM-DEPENDENT GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-08-31 | — | — | WO | disclosed |
| US-20060189548-A1 | Glucopyranosyl-substituted ((hetero)arylethynyl-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189548-A1 | Glucopyranosyl-substituted ((hetero)arylethynyl-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture | UGGT1, UGT2B7, GPR119 | SLC5A2 5/4885SLC5A1 9/4885ADRA2A 183/4885 |
| US-20070073046-A1 | Processes for preparing of glucopyranosyl-substituted (ethynyl-benzyl)-benzene derivatives and intermediates thereof | UGGT1, B3GAT3, UGCG | SLC5A2 180/4885SLC5A1 165/4885ADRA2A 1395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.